Market turmoil is tanking biotech M&A and IPOs. Here's the playbook startups will use to survive
It’s a biotech environment without many good choices.
Even before President Donald Trump’s tariff announcement pushed stock indices toward a bear market, biotech M&A has …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
